Loading
A phase 3 trial testing AL8326 in small-cell lung cancer and non-small-cell lung cancer, now recruiting.
A Phase IIII Study of AL8326 in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06247605, led by Advenchen Laboratories Nanjing, and recruiting on the registry. Official title: Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment. Planned enrolment is 243 participants (estimated). The study started in 2023-10-26 and primary completion is expected in 2028-07. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advenchen Laboratories, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Advenchen Laboratories, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/